Vivani Medical
Vivani Medical reported revenue of $0 million in fiscal 2025. Free cash flow was −$25 million. The diluted share count rose 13.5%.
Net margin is net income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Vivani Medical lost money in fiscal 2025: a net loss of $27 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 70 | 45 | 21 | 18 | 16 |
| Debt incl. finance leases | — | — | — | — | — |
| Net debt (negative means net cash) | — | — | — | — | — |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | — | — | — | — | — |
| Interest coverage | — | — | — | — | — |
| Current ratio | 1.2x | 7.0x | 4.0x | 3.4x | 2.7x |
| Quick ratio | — | 7.0x | 4.0x | 3.4x | 2.7x |
Cash flow
Projections
Project Vivani Medical's revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, 2 insiders bought $16.7 million of Vivani Medical shares on the open market, and none sold any.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Nov 17, 2026 | Gregg WilliamsDirector, 10% owner | Bought | 29,929 | $1.05 | $31,455 | Form 4 |
| Nov 16, 2026 | Gregg WilliamsDirector, 10% owner | Bought | 2,100 | $1.01 | $2,121 | Form 4 |
| Jul 15, 2026 | Gregg WilliamsDirector, 10% owner | Bought | 793,650 | $1.26 | $999,999 | Form 4 |
| Jun 15, 2026 | Gregg WilliamsDirector, 10% owner | Bought | 1,587,301 | $1.26 | $2.0 million | Form 4 |
| May 15, 2026 | Gregg WilliamsDirector, 10% owner | Bought | 1,587,301 | $1.26 | $2.0 million | Form 4 |
| Apr 15, 2026 | Gregg WilliamsDirector, 10% owner | Bought | 1,587,301 | $1.26 | $2.0 million | Form 4 |
| Mar 15, 2026 | Gregg WilliamsDirector, 10% owner | Bought | 1,575,231 | $1.07 | $1.7 million | Form 4 |
| Feb 15, 2026 | Gregg WilliamsDirector, 10% owner | Bought | 1,866,492 | $1.06 | $2.0 million | Form 4 |
| Jan 27, 2026 | Gregg WilliamsDirector, 10% owner | Bought | 1,351,351 | $1.48 | $2.0 million | Form 4 |
| Jan 15, 2026 | Gregg WilliamsDirector, 10% owner | Bought | 1,737,765 | $1.14 | $2.0 million | Form 4 |
| Dec 29, 2025 | Aaron MendelsohnDirector | Bought | 20,000 | $1.23 | $24,600 | Form 4 |
| Dec 15, 2025 | Gregg WilliamsDirector, 10% owner | Bought | 1,737,765 | $1.14 | $2.0 million | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | — | — | — |
| Rule of 40 | — | — | — |
| Altman Z'' | −7.61 | −10.50 | −14.41 |
| Accruals ratio | −4.0% | −6.2% | −5.7% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Fail | Fail |
| Cash from operations is positive | Fail | Fail | Fail |
| Return on assets rose | Pass | Fail | Fail |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | Fail | Fail | Fail |
| Share count didn't rise | — | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | Fail |
| F-score | — | — | — |
Compare
Put Vivani Medical side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Vivani Medical | FY25 | — | — | — | — | — | — | |
| AbbVie | FY25 | 8.6% | 24.6% | 29.1% | 15.7% | 2.7x | 7 | Compare |
| AbCellera Biologics | FY25 | 160.6% | −289.0% | −231.7% | — | — | — | Compare |
| Abeona Therapeutics | FY25 | — | −1,536.9% | −1,448.5% | — | — | — | Compare |
| Absci | FY25 | −38.2% | −4,297.0% | −3,358.3% | −162.8% | — | 3 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 4 | 8 | 7 | 3 | — | — | — | — | 0 | 0 |
| Revenue growth | −55.1% | 99.1% | −13.4% | −51.0% | — | — | — | — | — | — |
| Gross profit | −6 | 3 | 2 | 1 | 0 | 0 | — | — | — | — |
| Research and development | 5 | 8 | 10 | 13 | 5 | 11 | 14 | 17 | 16 | 18 |
| Operating income | −33 | −29 | −35 | −34 | −15 | −13 | −21 | −27 | −25 | −28 |
| Net income | −33 | −28 | −35 | −34 | −15 | −13 | −14 | −26 | −24 | −27 |
| Diluted EPS (US$) | −6.72 | −4.24 | −4.23 | −2.28 | −0.72 | −0.27 | — | −0.50 | −0.43 | −0.43 |
| Diluted shares (millions) | 5 | 7 | 8 | 15 | 21 | 33 | — | 51 | 55 | 62 |
| Cash flow | ||||||||||
| Cash from operations | −25 | −24 | −30 | −28 | −17 | −11 | −19 | −24 | −21 | −24 |
| Capital expenditure | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 1 |
| Free cash flow | −26 | −24 | −30 | −28 | −17 | −12 | −19 | −25 | −21 | −25 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Stock-based compensation | 3 | 4 | 4 | 3 | 0 | 2 | 1 | 2 | 2 | 2 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 21 | 15 | — | 11 | 3 | 70 | 45 | 21 | 18 | 16 |
| Debt incl. finance leases | — | — | — | — | — | — | — | — | — | — |
| Total assets | 17 | 14 | 11 | 17 | 4 | 6 | 51 | 46 | 42 | 39 |
| Total liabilities | 6 | 7 | 8 | 9 | 5 | 3 | 7 | 25 | 24 | 24 |
| Shareholders' equity | 11 | 8 | 3 | 7 | 2 | 2 | 44 | 21 | 18 | 16 |
| Margins and ratios | ||||||||||
| Gross margin | −152.3% | 35.8% | 29.1% | 36.3% | — | — | — | — | — | — |
| Operating margin | −830.2% | −359.2% | −510.1% | −1,004.9% | — | — | — | — | — | — |
| Net margin | −829.5% | −358.1% | −508.9% | −994.1% | — | — | — | — | — | — |
| Free cash flow margin | −639.0% | −304.0% | −434.6% | −832.3% | — | — | — | — | — | — |
| Rule of 40 (growth + FCF margin) | −694.1% | −204.9% | −448.1% | −883.3% | — | — | — | — | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −211.3% | −299.7% | −640.0% | −648.6% | −322.6% | −578.6% | −59.4% | −78.8% | −122.4% | −159.6% |
| Return on assets | −147.3% | −182.2% | −278.8% | −246.3% | −141.3% | −257.7% | −49.1% | −52.9% | −53.8% | −65.7% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |